Skip to main content

Table 4 Clinicopathological characteristics of breast cancer patients with high and low ACE2 expression

From: Chemotherapy induces ACE2 expression in breast cancer via the ROS-AKT-HIF-1α signaling pathway: a potential prognostic marker for breast cancer patients receiving chemotherapy

Variables

ACE2

P-value

Higher (> 14.78)

Lower (< 14.78)

N = 56

 N = 55

Mean-Age (years)

52.89

50.2

 

ACE2 (ng/mL)

21.23

9.71

 

Chemotherapy

   

 Chemotherapy-resistant

36(64.29%)

21(38.18%)

0.0059

 Chemotherapy-sensitive

20(35.71%)

34(61.81%)

Grade

   

 I

11(19.64%)

21(38.18%)

0.0311

 II–III

45(80.36%)

34(61.82%)

T

   

 T1

9(16.07%)

20(36.36%)

0.0040

 T2–T3

41(73.21%)

24(43.64%)

 Tx

2(3.57%)

11(20.00%)

 

N

   

 N0

19(33.93%)

28(3.63%)

0.0700

 N1–N2–N3

37(66.07%)

27(96.37%)

 

M

   

 M0

10(17.86%)

11(20.00%)

0.0077

 M1

36(64.29%)

9(16.36%)

 MX

10(17.86%)

35(63.63%)

 

Surgery

   

 Yes

33 (58.93%)

15 (27.27%)

0.0008

 No

23 (41.07%)

40 (72.72%)

Recurrence

   

 Yes

0 (0%)

1 (1.82%)

0.3108

 No

56 (100%)

54 (98.18%)

Metastasis

   

 Yes

6 (10.71%)

23 (41.82%)

0.0002

 No

50 (89.29%)

32 (58.18%)